Johnson Pharmacare (532154) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
13 Feb, 2026Executive summary
Board approved appointment of M/s VRSK & Associates as Statutory Auditor effective 13.02.2026 to fill a casual vacancy.
Ms. Parul Agrawal (DIN: 11268580) appointed as Additional Non-Executive & Independent Director.
Significant events and developments
Statutory Auditor change: M/s VRSK & Associates appointed, with consent and eligibility confirmed under Companies Act, 2013.
Ms. Parul Agrawal's appointment as Additional Non-Executive & Independent Director, with self-declaration of non-debarment as per SEBI (LODR), 2015.
Risk factors and uncertainties
No pending proceedings or disqualifications against the newly appointed auditor, as confirmed in their consent letter.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Johnson Pharmacare
- No revenue and continued net losses reported for the quarter ended September 30, 2025.532154
Q2 25/2618 Nov 2025 - Net loss narrowed for Q2 and H1 FY25, with negligible revenue and stable equity.532154Q2 24/2530 Oct 2025
- Profit recovery and portfolio upgrades contrast with a widened net loss in another period.532154Q1 25/2630 Jul 2025
- Net loss of ₹3.99 lakhs on revenue of ₹3.99 lakhs reported for Q1 FY25.532154Q1 24/2513 Jun 2025
- Net loss widened to Rs. 58.38 lakhs in FY25, driven by a SEBI penalty and no revenue.532154Q4 24/256 Jun 2025
- Q3 FY25 saw flat revenue and a net loss, with auditors raising no concerns.532154Q3 24/256 Jun 2025